GlassScriptPhysician profile
Hesamm E Gharavi
NPI 1487640892
$20,958.17
in general payments reported to CMS, 2019-2025
69 companies · $2,777 in 2025
The $2,777 reported for 2025 was more than what a typical Hematology & Oncology provider received nationally (typical 2025 total: $686).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $3,318 · 2020: $1,812 · 2021: $2,112 · 2022: $1,021 · 2023: $6,049 · 2024: $3,870 · 2025: $2,777.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $9,244 · Consulting Fee: $2,818 · Long Term Medical Supply Or Device Loan: $598 · Education: $35.25.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $9,244.36 |
| Consulting Fee | $2,818.00 |
| Long Term Medical Supply Or Device Loan | $598.20 |
| Education | $35.25 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Incyte Corporation | $3,321.70 | 2019-2025 | Monjuvi, Jakafi, Pemazyre |
| Novartis Pharmaceuticals Corporation | $1,766.68 | 2019-2025 | |
| Exelixis INC. | $1,744.79 | 2019-2025 | Cabometyx |
| Janssen Biotech, INC. | $998.53 | 2019-2025 | Tecvayli, Talvey, Darzalex |
| Astrazeneca Pharmaceuticals LP | $975.30 | 2019-2025 | Tagrisso, Enhertu, Calquence |
| Merck Sharp & Dohme LLC | $904.25 | 2019-2025 | Keytruda, Welireg, Lynparza |
| Pfizer INC. | $821.43 | 2019-2025 | |
| Celgene Corporation | $716.65 | 2020-2025 | Reblozyl, Pomalyst, Pomalyst |
| Amgen INC. | $676.95 | 2019-2023 | Lumakras, Kyprolis, Nplate |
| E.R. Squibb & Sons, L.L.C. | $599.43 | 2019-2025 | Opdualag, Pomalyst, Opdivo |
| Genentech USA, INC. | $581.51 | 2019-2025 | Tecentriq, Phesgo, Perjeta |
| Genzyme Corporation | $518.38 | 2019-2024 | |
| Abbvie INC. | $425.12 | 2019-2025 | |
| Seagen INC. | $421.67 | 2019-2023 | Adcetris, Padcev, Tukysa |
| Astellas Pharma US INC | $417.84 | 2019-2025 | Xtandi, Padcev, Vyloy |
Show all 69 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Daiichi Sankyo INC. | $400.28 | 2019-2025 | Enhertu, Injectafer |
| Takeda Pharmaceuticals U.S.A., INC. | $387.11 | 2019-2025 | Ninlaro, Alunbrig |
| Eisai INC. | $366.57 | 2020-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $354.90 | 2019-2025 | |
| Lilly USA, LLC | $305.79 | 2019-2025 | Jaypirca, Verzenio, Retevmo |
| Pharmacyclics LLC, An Abbvie Company | $302.94 | 2020-2023 | Imbruvica |
| Gilead Sciences, INC. | $284.36 | 2019-2025 | Trodelvy |
| Mirati Therapeutics, INC. | $259.57 | 2023-2024 | Krazati |
| Ipsen Biopharmaceuticals, INC | $238.34 | 2020-2025 | Onivyde |
| Array Biopharma INC | $229.16 | 2020-2025 | Mektovi, Braftovi, Lorbrena |
| Glaxosmithkline, LLC. | $217.65 | 2020-2025 | Jemperli, Ojjaara |
| Karyopharm Therapeutics INC. | $204.47 | 2021-2025 | Xpovio |
| Puma Biotechnology, INC. | $164.47 | 2020-2025 | Nerlynx |
| Regeneron Healthcare Solutions, INC. | $163.02 | 2019-2025 | Libtayo, Lynozyfic |
| Deciphera Pharmaceuticals INC. | $160.77 | 2021-2025 | Qinlock, Romvimza |
| Kyowa Kirin, INC. | $133.90 | 2019-2025 | Poteligeo |
| Galvanize Therapeutics, INC | $115.58 | 2025 | Aliya System |
| Beigene USA, INC. | $115.02 | 2020-2025 | Brukinsa |
| Aveo Pharmaceuticals, INC. | $109.25 | 2022-2024 | Fotivda |
| Sobi, INC | $100.81 | 2022-2025 | |
| Kite Pharma, INC. | $93.13 | 2020-2025 | Yescarta |
| Tersera Therapeutics LLC | $89.42 | 2023-2025 | Zoladex, Xermelo |
| Alexion Pharmaceuticals, INC. | $85.42 | 2019-2025 | Ultomiris |
| Emd Serono, INC. | $83.42 | 2019-2024 | |
| Beone Medicines USA, INC. | $81.24 | 2025 | Brukinsa, Tevimbra |
| Jazz Pharmaceuticals INC. | $78.86 | 2022-2025 | |
| Myriad Genetic Laboratories, INC. | $78.06 | 2021-2024 | Precisetumor |
| Springworks Therapeutics, INC. | $67.18 | 2024-2025 | Ogsiveo |
| Boehringer Ingelheim Pharmaceuticals, INC. | $61.08 | 2019-2025 | Gilotrif |
| Agios Pharmaceuticals, INC. | $51.60 | 2019-2020 | |
| Epizyme, INC. | $45.68 | 2020-2021 | |
| Tesaro, INC. | $43.29 | 2019 | |
| Stemline Therapeutics INC. | $40.68 | 2021-2022 | |
| Teva Pharmaceuticals USA, INC. | $40.60 | 2019 | |
| Genmab U.S., INC. | $38.81 | 2023 | Epkinly |
| Secura Bio, INC. | $38.17 | 2020-2022 | |
| Blueprint Medicines Corporation | $38.04 | 2025 | Ayvakit |
| Pharmaessentia USA Corporation | $33.78 | 2024 | Besremi |
| Clovis Oncology, INC. | $32.17 | 2020-2021 | |
| Pharmacosmos Therapeutics INC. | $29.15 | 2021-2023 | Monoferric |
| Adc Therapeutics America, INC. | $28.67 | 2023 | |
| Myovant Sciences INC. | $28.65 | 2022 | |
| Janssen Pharmaceuticals, INC | $27.11 | 2019 | |
| Alnylam Pharmaceuticals INC. | $24.22 | 2020-2022 | |
| Dova Pharmaceuticals | $24.03 | 2020-2021 | |
| Geron Corporation | $23.72 | 2024 | Rytelo |
| Caris Mpi, INC. | $21.07 | 2025 | Mi Cancer Seek |
| Servier Pharmaceuticals LLC | $20.64 | 2024 | |
| Organon LLC | $20.48 | 2023 | |
| Rigel Pharmaceuticals, INC. | $20.39 | 2021 | |
| Lexicon Pharmaceuticals, INC. | $18.57 | 2019 | |
| Acceleron Pharma, INC. | $17.31 | 2021 | |
| Sun Pharmaceutical Industries INC. | $15.51 | 2024 | |
| Taiho Oncology, INC. | $13.83 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Hesamm Gharavi listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.